For cancers of the breast, BrM occurs after diagnosis of systemic metastases from tumors belonging to one of two categories: tumors with amplification of ErbB2 or TNBC; the incidence of both exceeds one-third of patients [47, 48]. This evidence concerns the gene ERBB2 and breast cancer.